OncoMatch/Clinical Trials/NCT05343013
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Is NCT05343013 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TAS-102 for colorectal cancer.
Treatment: TAS-102 — To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy (oxaliplatin) — adjuvant
has completed all planned curative intent therapies that must include 3 months of oxaliplatin containing chemotherapy
Lab requirements
Blood counts
absolute neutrophil count: 1,000/mcL; platelets: 100,000/mcL
Kidney function
Serum creatinine 1.5 00 ULN or creatinine clearance 60 mL/min
Liver function
total bilirubin: institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT): 3 0 institutional ULN
Has adequate organ and marrow function as defined below: 1. absolute neutrophil count: 1,000/mcL 2. platelets: 100,000/mcL 3. total bilirubin: institutional upper limit of normal (ULN) 4. AST(SGOT)/ALT(SGPT): 3 00 institutional ULN 5. Serum creatinine 1.5 00 ULN or creatinine clearance 60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify